Clinician's Pocket Drug Reference 2015

Total Page:16

File Type:pdf, Size:1020Kb

Clinician's Pocket Drug Reference 2015 TIPS FOR SAFE PRESCRIPTION WRITING** 1. Take time to write legibly. 2. Print if this would be more legible than handwriting. 3. Use a typewriter or computer if necessary. Prescriptions generated by computer- based electronic medical records will eliminate legibility problems. 4. Carefully print the order to avoid misreading. There are many “sound alike” drugs and medications that have similar spellings (ie, Celexa and Celebrex). For a more extensive list, see www.edrugbook.com. 5. Do not use these clinical abbreviations The Correct Way Do Not Use Problem daily qd Misinterpreted as “qid” (resulting in 4-fold overdose) q other day or qod Misinterpreted as “qid” or “qd” q48 hours units u or U Misinterpreted as a “0” (resulting in a 10-fold overdose) 1 mg 1.0 mg Decimal point can be missed (no trailing zero) on order (resulting in a 10-fold overdose) 0.1 mg .1 mg Decimal point can be missed (use a leading zero) on order (resulting in a 10-fold overdose) international units IU Misinterpreted as “IV” morphine MS, MSO4 Misinterpreted as magnesium sulfate magnesium sulfate MgSO4 Misinterpreted as morphine sulfate **Adapted with permission from Gomella LG, Haist SA, eds. Clinician’s Pocket Reference 11th Edition. New York, NY: McGraw-Hill; 2007. Based on recom- mendations for the use of abbreviations from the National Summit on Medical Abbreviations hosted by The Joint Commission CLINICIAN’S POCKET DRUG REFERENCE 2015 EDITORS Leonard G. Gomella, MD, FACS Steven A. Haist, MD, MS, FACP Aimee G. Adams, PharmD www.eDrugbook.com www.thescutmonkey.com New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto Copyright © 2015 by Leonard G. Gomella. Published by McGraw-Hill Education. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher, with the exception that the program listings may be entered, stored, and executed in a computer system, but they may not be reproduced for publication. ISBN: 978-0-07-184001-9 MHID: 0-07-184001-X The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-184000-2, MHID: 0-07-184000-1. eBook conversion by codeMantra Version 1.0 All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps. McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a representative, please visit the Contact Us page at www.mhprofessional.com. Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources that are believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. TERMS OF USE This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill Education’s prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms. THE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise. CONTENTS EDITORS V EDITORIAL BOARD VI PREFACE VII MEDICATION KEY IX ABBREVIATIONS XI CLASSIFICATION 1 Allergy 1 Antidotes 1 Antimicrobial Agents 2 Antineoplastic Agents 6 Cardiovascular (CV) Agents 8 Central Nervous System (CNS) Agents 12 Dermatologic Agents 15 Dietary Supplements 17 Ear (Otic) Agents 17 Endocrine System Agents 17 Eye (Ophthalmic) Agents 20 Gastrointestinal (GI) Agents 22 Hematologic Agents 24 Immune System Agents 25 Musculoskeletal Agents 26 OB/GYN Agents 27 Pain Medications 28 Respiratory Agents 30 Urogenital System 32 iii iv Contents GENERIC AND SELECTED BRAND DRUG DATA 37 NATURAL AND HERBAL AGENTS 311 TABLES 317 Table 1 Local Anesthetic Comparison Chart for Commonly Used Injectable Agents 318 Table 2 Comparison of Systemic Steroids 319 Table 3 Topical Steroid Preparations 320 Table 4 Comparison of Insulins 322 Table 5 Oral Contraceptives 325 Table 6 Oral Potassium Supplements 335 Table 7 Tetanus Prophylaxis 336 Table 8 Oral Anticoagulant Standards of Practice 337 Table 9 Antiarrhythmics: Vaughn Williams Classification 339 Table 10 Cytochrome P–450 Isoenzymes and Common Drugs They Metabolize, Inhibit, and Induce 340 Table 11 SSRIs/SNRIs/Triptans and Serotonin Syndrome 342 Table 12 Selected Multivitamin Supplements 343 Table 13 Influenza Vaccine Strains for 2014–2015 346 INDEX 347 TIPS FOR SAFE PRESCRIPTION WRITING Inside Front Cover ADULT EMERGENCY CARDIAC CARE (ECC) MEDICATIONS BASED ON 2010 AHA GUIDELINES Back Page and Inside Back Cover EDITORS Leonard G. Gomella, MD, FACS The Bernard W. Godwin, Jr, Professor Chairman, Department of Urology Sidney Kimmel Medical College Associate Director of Clinical Affairs Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia, Pennsylvania Steven A. Haist, MD, MS, FACP Clinical Professor Department of Medicine Drexel University College of Medicine, Philadelphia, Pennsylvania Aimee G. Adams, PharmD Clinical Pharmacist Specialist, Ambulatory Care Adjunct Assistant Professor College of Pharmacy and Department of Internal Medicine University of Kentucky HealthCare Lexington, Kentucky v EDITORIAL BOARD Carol L. Beck, PhD Glenn R. Oettinger, PharmD Assistant Dean, Jefferson College of Clinical Pharmacist, Emergency Graduate Studies Medicine Assistant Professor Thomas Jefferson University Dept. of Pharmacology & Hospital Experimental Therapeutics Philadelphia, Pennsylvania Thomas Jefferson University Philadelphia, Pennsylvania Nick A. Pavona, MD Professor, Department of Surgery Patrick T. Gomella, MD, MPH Division of Urology Resident Department of Urology Benjamin Franklin University George Washington University Medical Center Washington, DC Chadds Ford, Pennsylvania Tricia L. Gomella, MD Andrew Stacy, PharmD Part-Time Clinical Assistant PGY-1 Pharmacy Resident Professor of Pediatrics Baptist Health Johns Hopkins University School of Lexington, Kentucky Medicine Baltimore, Maryland vi PREFACE We are pleased to present the 13th edition of the Clinician’s Pocket Drug Reference. This book is based on the drug presentation style originally used in 1983 in the Clinician’s Pocket Reference, popularly known as the Scut Monkey Book. Our goal is to identify the most frequently used and clinically important medications, including branded, generic, OTC, and herbal products. The book now includes over 1400 generic product listings with the true number approaching 4000 entries when specific brand names are considered. Our unique style of presentation includes key “must-know” facts of commonly used medications, essential for both the student and practicing clinician. The inclu- sion of common uses of medications rather than just the official FDA-labeled indi- cations are based on supporting publications and community standards of care and have been reviewed by our editors and editorial board.
Recommended publications
  • Download This PDF File
    Chimica Analitica ANA-KN-01 Functionalized carbon nanostructures and metal nanoparticles: from effective charge propagation to enhancement of electrocatalytic, photoelectrocatalytic and bioelectrocatalytic properties Pawel J. Kulesza Department of Chemistry, University of Warsaw, Pasteura 1, PL-02-093 Warsaw, Poland * [email protected] Of particular interest to the preparation of advanced materials is synthesis and characterization of carbon nanostructures (e.g. nanotubes) and noble metal nanoparticles, their stabilization (e.g. through self-assembly), as well as organization into two-dimensional arrays and controlled fabrication (e.g. through the sequential attraction) into three-dimensional network films. They can form nanosized materials with well-defined composition, structure and thickness. The interfaces can be also highly functionalized, and they can exhibit specific catalytic or unique electronic, charge storage, optical and sensing properties. We explore here the ability of inorganic structures to stabilize and derivatize metal and carbon nanostructures. Among inorganic systems, polyoxometallates of molybdenum and tungsten are attractive since they can not only adsorb irreversibly on solid surfaces but also exhibit reversible stepwise multielectron transfer reactions. The concept of the layer-by-layer formation of hybrid (organic-inorganic) assemblies composed of anionic polyoxometallate-protected carbon nanotubes (or metal nanoparticles) and ultra-thin films of positively charged conducting polymers (e.g. such as polyaniline or PEDOT) will be described and discussed here. The resulting novel composite materials have been fabricated as thin or moderately thick (µm level) films on electrode surfaces. As evidenced from STM and scanning electron microscopy, their morphology is still granular but the structure is fairly dense. Further, they are characterized by fast dynamics of charge propagation.
    [Show full text]
  • University of Birmingham Uterotonic Agents for Preventing Postpartum
    University of Birmingham Uterotonic agents for preventing postpartum haemorrhage Gallos, Ioannis D; Williams, Helen M; Price, Malcolm J; Merriel, Abi; Gee, Harold; Lissauer, David; Moorthy, Vidhya; Tobias, Aurelio; Deeks, Jonathan J; Widmer, Mariana; Tunçalp, Özge; Gülmezoglu, Ahmet Metin; Hofmeyr, G Justus; Coomarasamy, Arri DOI: 10.1002/14651858.CD011689.pub2 License: None: All rights reserved Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Gallos, ID, Williams, HM, Price, MJ, Merriel, A, Gee, H, Lissauer, D, Moorthy, V, Tobias, A, Deeks, JJ, Widmer, M, Tunçalp, Ö, Gülmezoglu, AM, Hofmeyr, GJ & Coomarasamy, A 2018, 'Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis', Cochrane Database of Systematic Reviews, vol. 2018, no. 4, CD011689. https://doi.org/10.1002/14651858.CD011689.pub2 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility:17/05/2018 Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ, Widmer M, Tunçalp Ö, Gülmezoglu AM, Hofmeyr GJ, Coomarasamy A. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD011689. DOI: 10.1002/14651858.CD011689.pub2. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication.
    [Show full text]
  • Testing Kits for Kinesiologists & Natural Therapists
    Testing Kits for Kinesiologists & Natural Therapists The kits come in easy seal bags and boxes are available separately for storage if required (see below). Postage will range from $7.00 to $13.00 ($12 to $26 for Express). The prices of these kits may change from time to time. Please check before or when ordering as to any prices changes. Individual vials may be purchased from kits for $17 each (or $13 each for 7 or more). Other single vials & update vials - see pages back of manual This manual is available at $29.00 plus $7.00 postage. With kit purchases it is available at a basic price of $19.00. After an initial purchase, any updated or later editions can be purchased at $15.00 plus $7.00 postage. Testing Kit Boxes & Empty Vials: Test Kit Box for 50 Vials (plastic box - vials upright): $13.00 or $10.00 with kits Test Kit Box for 100 Vials (plastic box - vials upright): $17.00 or $14.00 with Kits Test Kit Box for 72 vials (flat cardboard box with foam inlay – vials lay flat): $42 or $35 with kits Empty Vials for Liquids: 8 x 40 mm glass vial with plastic top: $6.00 per 10 vials or $52.00 per 100 pack. Empty Vials for Solids: 10 x 40mm glass vial with plastic top: $8.00 per 10 vials or $69.00 per 100 pack Pathology & Histology Testing Kits A Range of Kinesiological Testing Kits for Anatomy & Pathologies of the Body Organs & Systems (contents lists included in this manual) see contents page 3 Flower Essences We supply a variety of Flower Essences, and other types of Essences, plus accessories.
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Malaysian Statistics on Medicines 2009 & 2010
    MALAYSIAN STATISTICS ON MEDICINES 2009 & 2010 Edited by: Siti Fauziah A., Kamarudin A., Nik Nor Aklima N.O. With contributions from: Faridah Aryani MY., Fatimah AR., Sivasampu S., Rosliza L., Rosaida M.S., Kiew K.K., Tee H.P., Ooi B.P., Ooi E.T., Ghan S.L., Sugendiren S., Ang S.Y., Muhammad Radzi A.H. , Masni M., Muhammad Yazid J., Nurkhodrulnada M.L., Letchumanan G.R.R., Fuziah M.Z., Yong S.L., Mohamed Noor R., Daphne G., Chang K.M., Tan S.M., Sinari S., Lim Y.S., Tan H.J., Goh A.S., Wong S.P., Fong AYY., Zoriah A, Omar I., Amin AN., Lim CTY, Feisul Idzwan M., Azahari R., Khoo E.M., Bavanandan S., Sani Y., Wan Azman W.A., Yusoff M.R., Kasim S., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Suganthi T., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I, Wan Hamilton W.H., Zaridah S., Maisarah A.H., Rohan Malek J., Selvalingam S., Lei C.M., Hazimah H., Zanariah H., Hong Y.H.J., Chan Y.Y., Lin S.N., Sim L.H., Leong K.N., Norhayati N.H.S, Sameerah S.A.R, Rahela A.K., Yuzlina M.Y., Hafizah ZA ., Myat SK., Wan Nazuha W.R, Lim YS,Wong H.S., Rosnawati Y., Ong S.G., Mohd. Shahrir M.S., Hussein H., Mary S.C., Marzida M., Choo Y. M., Nadia A.R., Sapiah S., Mohd. Sufian A., Tan R.Y.L., Norsima Nazifah S., Nurul Faezah M.Y., Raymond A.A., Md.
    [Show full text]
  • Traditional Preparations Used As Uterotonics in Sub‐
    International Journal of Gynecology and Obstetrics 120 (2013) 16–22 Contents lists available at SciVerse ScienceDirect International Journal of Gynecology and Obstetrics journal homepage: www.elsevier.com/locate/ijgo REVIEW ARTICLE Traditional preparations used as uterotonics in Sub-Saharan Africa and their pharmacologic effects Vandana Tripathi a,⁎, Cynthia Stanton a, Frank W.J. Anderson b a Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA b Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA article info abstract Article history: Background: Little is known about the use of traditional preparations for uterotonic effects at or near delivery Received 17 March 2012 in Sub-Saharan Africa. Objective: To describe (1) use of traditional preparations in Sub-Saharan Africa Received in revised form 25 June 2012 intended to have uterotonic effects at or near birth; and (2) results of pharmacologic investigations of the Accepted 23 August 2012 uterotonic properties of such preparations. Search strategy: Structured review of 13 databases. Selection criteria: Articles describing use of traditional preparations in Sub-Saharan Africa with primary data, published Keywords: in English between January 1, 1980 and June 30, 2010. Data collection and analysis: Full-text review using Labor augmentation standard spreadsheet templates. Main results: Objective 1 analysis identified 208 plant species used for Pharmacologic effects Plant species uterotonic effects at or near delivery. The most common use was labor induction/augmentation (n=185). Postpartum hemorrhage Other uses were to expel the placenta, shorten the third stage of labor, manage retained placenta (n=61), Retained placenta and prevent/manage postpartum hemorrhage (n=20).
    [Show full text]
  • Second Generation Antiarrhythmic Agents: Have We Reached Antiarrhythmic Nirvana?
    JACC Vol. 9. NO.2 459 February 1987:459-63 EDITORIAL REVIEWS Second Generation Antiarrhythmic Agents: Have We Reached Antiarrhythmic Nirvana? LEONARD N. HOROWITZ, MD, FACC, JOEL MORGANROTH, MD, FACC Philadelphia, Pennsylvania During the first half of the 20th century, antiarrhythmic some cases novel, but because their preapproval evaluations therapy was principally directed toward supraventricular ar­ followed a more rigorous and circumspect path. More in­ rhythmia; only relatively recently has therapy of ventricular formation is available to us so we can decide when and how arrhythmias been emphasized. In fact, significant pharma­ these agents should be employed. cologic treatment of ventricular arrhythmias was minimal Like all antiarrhythmic drugs of the first generation, the until routine use of quinidine and procainamide began in new agents have the potential to provoke or worsen ven­ the 1950s (1,2). The first generation oral antiarrhythmic tricular arrhythmias. These proarrhythmic effects vary in drugs, quinidine, procainamide and disopyramide, previ­ incidence and may present a major problem in certain patient ously constituted the principal antiarrhythmic agents for long­ groups such as those with sustained ventricular tachyar­ term treatment of ventricular arrhythmias in the United States. rhythrnias, reduced left ventricular function and conduction Compared with modem regulatory standards, the data on disturbances. In common with other antiarrhythmic drugs, which the use of these drugs was based were modest at best the second generation drugs have not been shown to prevent and rudimentary at worst. However, because good clinical sudden death in patients with ventricular ectopic activity. judgment compensates for a multitude of deficiencies, we These factors, along with efficacy and potential toxicity, have been able to provide effective antiarrhythmic therapy must be considered in selecting antiarrhythmic regimens for to many patients with this rather limited pharmacopoeia.
    [Show full text]
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Rational Use of Uterotonic Drugs During Labour and Childbirth
    Prevention and initial management of postpartum haemorrhage Rational use of uterotonic drugs during labour and childbirth Prevention and treatment of postpartum haemorrhage December 2008 Editors This manual is made possible through sup- Prevention of postpartum hemorrhage port provided to the POPPHI project by the initiative (POPPHI) Office of Health, Infectious Diseases and Nu- trition, Bureau for Global Health, US Agency for International Development, under the POPPHI Contacts terms of Subcontract No. 4-31-U-8954, under Contract No. GHS-I-00-03-00028. POPPHI is For more information or additional copies of implemented by a collaborative effort be- this brochure, please contact: tween PATH, RTI International, and Engen- Deborah Armbruster, Project Director derHealth. PATH 1800 K St., NW, Suite 800 Washington, DC 20006 Tel: 202.822.0033 Susheela M. Engelbrecht Senior Program Officer, PATH PO Box 70241 Overport Durban 4067 Tel: 27.31.2087579, Fax: 27.31.2087549 [email protected] Copyright © 2009, Program for Appropriate Tech- www.pphprevention.org nology in Health (PATH). All rights reserved. The material in this document may be freely used for educational or noncommercial purposes, provided that the material is accompanied by an acknowl- edgement line. Table of contents Preface………………………………………………………………………………………………………………………………………………….3 Supportive care during labour and childbirth…………………………………………………………………………………….4 Rational use of uterotonic drugs during labour………………………………………………………………………………...5 Indications and precautions for augmentation
    [Show full text]
  • Formulation Development Strategies
    FORMULATION DEVELOPMENT STRATEGIES FOR ORAL EXTENDED RELEASE DOSAGE FORMS Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von ARAYA RAIWA aus Bangkok, Thailand May, 2011 1. Gutachter: Prof. Dr. Roland Bodmeier 2. Gutachter: Prof. Dr. Jürgen Siepmann Disputation am 9.Juni 2011 TO MY FAMILY ACKNOWLEDGEMENTS First and foremost, I wish to express my deepest gratitude to my supervisor, Prof. Dr. Roland Bodmeier for his professional guidance, helpful advices and encouragement. I am very grateful for his scientific and financial support and for providing me such an interesting topic. Furthermore, I am very thankful to him for the opportunity to support his editorial role in the European Journal of Pharmaceutical Sciences. I would like to thank Prof. Dr. Jürgen Siepmann for co-evaluating this thesis. Thanks are extended to Prof. Dr. Herbert Kolodziej, Prof. Dr. Johannes Peter Surmann and Dr. Martin Körber for serving as members of my thesis advisor committee. I am particular thankful to Dr. Andrei Dashevsky, Dr. Nantharat Pearnchob and Dr. Martin Körber for their very useful discussion; Dr. Burkhard Dickenhorst for evaluating parts of this thesis; Mrs. Angelika Schwarz for her assistance with administrative issues; Mr. Andreas Krause, Mrs. Eva Ewest and Mr. Stefan Walter for the prompt and diligent technical support. Sincere thanks are extended to Dr. Ildiko Terebesi, Dr. Burkhard Dickenhorst, Dr. Soravoot Rujivipat and Dr. Samar El-Samaligy for the friendly atmosphere in the lab My special thanks are owing to all members from the Kelchstrasse for their practical advice, enjoyable discussion and kindness throughout the years.
    [Show full text]
  • The Carnivore Code Paul Saladino, M.D
    By dag Forssell, Jan 23, 2021 Comments: [email protected] Salicylates as discussed in The Carnivore Code Paul Saladino, M.d. CHAPTER 5: OF UNICORNS AND FAIRY TALES PERHAPSCHAPTER MORE THAN 6: ATTACKany other plant OF molecule,THE OXALATES polyphenols have become associated with the term “superfoods.” They are often dubbed “antioxidants,” and we are told to consume as much of them as possible. It seemsIN THE that FREQUENTLYPREVIOUS every day, two another chapters, ASKEDcompany we talked comes QUESTIONS about out plant with defense a supposedly chemicals magicalthat can supplement, have damaging juice, effectsor powder in ourwith bodiesbold claimsbecause of they’redecreased not inflammationcompatible with and ourlongevity human as operating it touts itssystem. robust In polyphenol this chapter, content. we’re Let’sgoing WHEN I STARTED writing this book, I knew that I would never be able to talkto talkabout about what apolyphenols molecule that actually is produced are and inwhy small we’ve quantities been told as they a waste are address every single possible question that arose from it—that’s what my 2223-2228.Textgoodproduct excerpted for ofus. human Then from metabolismwe’ll thesediscuss but chapters, why occurs I’m in going veryfollowed largeto take amounts bythe text,radically in some tables, next books are for. In an effort to be as comprehensive as possible, 38. Lawrence,contraryplants, andviewpointJ. R.,can Peter,cause that serious theirR., Baxter,purported pain, kidney G. benefits J., stones, Robson, are andnothing other J., moreGraham, issues than when the A. it B., & however,and I am comments including this copied section from to address the manyweb commonlypage listed asked stuffaccumulates of imagination, in our body.
    [Show full text]
  • The Effect of Biological Treatment on Behavior and Communication of Children on the Autistic Spectrum
    The Effect of Biological Treatment on Behavior and Communication of Children on the Autistic Spectrum Thesis submitted for the degree of Doctor of Philosophy At the University of Natural Medicine, Santa Fe by Anva Ohn-Bar, M.S. OTR Amirim, Israel May, 2006 Acknowledgements I would like to thank all the people who assisted me in this difficult and complicated project. First and foremost I thank and I appreciate the 9 families of the Autistic and PDD children, who cooperated, received my counseling and took my advice. I know how difficult it was. The beneficial changes most of them brought to their children's lives had an important influence on me. It was frustrating not to get cooperation from the rest of the families, and only because of the ones who did implement the program, I had the energy to continue and believe in what I do. I thank Annette Kahan, PhD. for all her assistance, wise feedback and expert comments. I thank Dr. Adiel Tel-Oren, for his support and useful comments and ideas. I also thank my family, who had to put up with a very busy and tired mother all this time…and especially my son Eshed, who helped me so much with the computer, the charts and all the technical part of writing… And last but not least, my husband Ohn, who supported me throughout the process. Without his love and patience I would have never completed this project. i Table of Contents Page Abstract iv Chapter 1: Introduction – why did I choose this subject? 1 The problem and the purpose of the study Chapter 2: Literature Review 5 Introduction - The spectrum of Neuro-behavioral disorders 5 A.
    [Show full text]